文献速递血液净化与透析

维持性透析患者SARS-CoV-2 mRNA疫苗的免疫原性

Immunogenicity of SARS-CoV-2 Vaccine in Dialysis.
PubMed 文献 · J Am Soc Nephrol · 2021-08-04

研究纳入186例维持性透析患者,接种两剂SARS-CoV-2 mRNA疫苗后至少14天检测抗体,88.7%为血清阳性,不同疫苗间无显著差异;有COVID-19史者全部应答,无史者85.8%应答。提示短期抗spike抗体应答良好,但需长期评估抗体持久性和加强针必要性。

要点

  • 透析患者接种两剂mRNA疫苗后88.7%产生抗体应答。
  • BNT162b2与mRNA-1273应答率无显著差异(P=0.42)。

核心结论

  • 多数维持性透析患者接种两剂BNT162b2或mRNA-1273后产生抗spike抗体,短期免疫原性良好。
  • 需长期评估抗体滴度持久性及加强针的必要性。
  • 对无血清学应答者的管理策略需进一步研究。

研究设计与样本

  • 回顾性队列研究,纳入2021年3月18日前电子健康记录中接受两剂SARS-CoV-2 mRNA疫苗且第二剂后≥14天有抗体检测结果的维持性透析患者。
  • 共186例患者来自8个州30家透析中心,抗体检测在第二剂后23±8天进行。
  • 采用FDA批准的半定量化学发光法(ADVIA Centaur XP/XPT COV2G)检测抗S1受体结合域IgG,≥2 U/L为血清阳性。

主要发现

  • 186例中165例(88.7%)为应答者,其中70%达最大滴度。
  • BNT162b2组应答率88.1%(148/168),mRNA-1273组94.4%(17/18),P=0.42。
  • 有COVID-19史者38例全部应答,97%达最大滴度。
  • 无COVID-19史者应答率85.8%(127/148),BNT162b2组85.0%(113/133)与mRNA-1273组93.3%(14/15)比较P=0.38。

临床怎么用

  • 透析患者接种两剂mRNA疫苗后多数可产生短期抗体应答,支持接种策略。
  • 对有COVID-19史者抗体应答率高,无史者应答率稍低但仍较高。
  • 需监测抗体滴度持久性,并研究无应答者的加强免疫策略。

局限性

  • 回顾性研究,抗体检测时间不一(23±8天)。
  • 样本量有限,mRNA-1273组仅18例。
  • 未评估长期抗体持久性和临床保护效力。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Patients receiving maintenance dialysis represent a high-risk, immune-compromised population with 15%-25% COVID-19 mortality rate who were unrepresented in clinical trials of mRNA vaccines. METHODS: All patients receiving maintenance dialysis who received two doses of SARS-CoV-2 mRNA vaccines with antibody test results drawn ≥14 days after the second dose, as documented in the electronic health record through March 18, 2021, were included. Response was on the basis of levels of Ig-G against the receptor binding domain of the S1 subunit of SARS-CoV-2 spike-antigen (seropositive ≥2 U/L) using an FDA-approved semiquantitative chemiluminescent assay (ADVIA Centaur XP/XPT COV2G). RESULTS: Among 186 patients on dialysis from 30 clinics in eight states tested 23±8 days after receiving two vaccine doses, there were 165 (88.7%) responders with 70% at maximum titer. There was no significant difference between BNT162b2/Pfizer (148 out of 168, 88.1%) and mRNA-1273/Moderna (17 out of 18, 94.4%), P=0.42. All 38 patients with COVID-19 history were responders, with 97% at maximum titer. Among patients without COVID-19, 127 out of 148 (85.8%) were responders, comparable between BNT162b2/Pfizer (113 out of 133) and mRNA-1273/Moderna (14 out of 15) vaccines (85.0% versus 93.3%, P=0.38). CONCLUSIONS: Most patients receiving maintenance dialysis responded after two doses of BNT162b2/Pfizer or mRNA-1273/Moderna vaccine, suggesting the short-term development of antispike antibody is good, giving hope that most of these patients who are vulnerable, once immunized, will be protected from COVID-19. Longer-term evaluation is needed to determine antibody titer durability and if booster dose(s) are warranted. Further research to evaluate the approach to patients without a serologic response is needed, including benefits of additional dose(s) or administration of alternate options.

来源:J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Lacson E, Argyropoulos CP, Manley HJ, et al. Immunogenicity of SARS-CoV-2 Vaccine in Dialysis. J Am Soc Nephrol. 2021. PMID: 34348908. doi:10.1681/ASN.2021040432

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。